Twist Bioscience CORP Form 4 insider transactions

Director Keith Crandell reports acquisition of Twist Bioscience shares through an equity award and discloses beneficial ownership.

Director Jan Johannessen reports acquiring 4,472 shares of Twist Bioscience common stock on February 5, 2025, through an equity award.

Director Robert Ragusa reports acquiring and disposing of Twist Bioscience Corp common stock on February 5, 2025.

Director Melissa A. Starovasnik reports acquisition of 4,472 shares of Twist Bioscience common stock and disposal of shares.

Director Robert Chess reports acquiring 4,472 shares of Twist Bioscience Corp stock and beneficially owning 21,113 shares directly and 42,528 indirectly through a trust.

Director Chan Nelson C acquired 4,472 shares of Twist Bioscience Corp common stock on February 5, 2025, and disposed of 28,156 shares.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, sold 185 shares of common stock on February 3, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Emily Leproust, CEO of Twist Bioscience, sold 5,200 shares of common stock on February 3, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 1,259 shares of common stock on February 3, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Patrick John Finn, President and COO of Twist Bioscience, sold 2,845 shares of common stock on February 3, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Dennis Cho, a Senior Vice President at Twist Bioscience Corp, sold 806 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Patrick John Finn, President and COO of Twist Bioscience, sold 2,422 shares of common stock on January 23, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Adam Laponis, CFO of Twist Bioscience, sold 5,886 shares of common stock on January 10, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Director Robert Chess of Twist Bioscience Corp. sold 5,000 shares of common stock at $50 per share on January 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.

A Twist Bioscience executive sold 144 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Twist Bioscience's President and COO, Patrick John Finn, sold 229 shares of common stock to cover tax obligations related to vesting restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 160 shares of common stock to cover tax obligations related to vesting restricted stock units.

Twist Bioscience CEO Emily M. Leproust sold 546 shares of common stock to cover tax obligations related to vesting restricted stock units.

Twist Bioscience director Robert Chess exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 316 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience Corp, sold 282 shares of common stock on December 20, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

CEO of Twist Bioscience, Emily Leproust, sold 1,654 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Dennis Cho, a Twist Bioscience executive, sold 133 shares of common stock on December 16, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

A Twist Bioscience executive sold shares to cover tax obligations related to the vesting of restricted stock units.

A Twist Bioscience executive sold shares to cover tax obligations related to vesting restricted stock units.

Twist Bioscience CEO Emily Leproust sold 2,216 shares of common stock to cover tax obligations related to vesting restricted stock units.

A Twist Bioscience executive sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Twist Bioscience CEO Emily Leproust reported the acquisition of 95,350 shares of common stock and various transactions related to employee stock options.

Twist Bioscience's President and COO, Patrick John Finn, was granted 53,634 restricted stock units on December 4, 2024.

Twist Bioscience's Chief Financial Officer, Adam Laponis, acquired 26,745 restricted stock units on December 4, 2024.